Abstract. Tumor necrosis factor alpha (TNFα)-induced protein 1 (TNFAIP1) was originally identified as a protein involved in DNA replication, DNA damage repair, apoptosis and the progression of certain diseases, such as Alzheimer's disease. In the present study, forskolin, a stimulant of cyclic adenosine monophosphate (cAMP), was found to significantly reduce human TNFAIP1 mRNA levels and TNFAIP1 promoter activity in the SKNSH human neuroblastoma cell line as indicated by polymerase chain reaction analysis and a luciferase reporter assay. The association between transcription factor cAMP response element-binding protein (CREB) and TNFAIP1 was further investigated using loss-and gain of function-studies with western blot analysis and luciferase reporter assays. The CREB-specific inhibitor KG-501 significantly increased TNFAIP1 protein levels, while overexpression of wild-type CREB, but not CREB mutated at ser133a or its DNA-binding site, significantly decreased human TNFAIP1 protein levels and TNFAIP1 promoter activity in SKNSH cells. Furthermore, two CRE sites located at -285 and -425 bp of the human TNFAIP1 promoter were identified to be responsible for CREB-induced inhibition of human TNFAIP1 promoter activity. Chromatin immunoprecipitation assays confirmed that CREB bound to the TNFAIP1 promoter region harboring these two CRE sites. A further luciferase reporter assay demonstrated that CREB phosphorylation on ser133 was responsible for forskolin-induced inhibition of TNFAIP1 expression. In conclusion, the present study suggested that CREB is a negative regulator of the TNFAIP1 gene.
Introduction
Tumor necrosis factor alpha (TNFα)-induced protein 1 (TNFAIP1) was originally identified as a gene whose expression can be induced by TNFα in umbilical vein endothelial cells (1) . TNFAIP1 is a highly conserved single-copy gene (1) , implying that TNFAIP1 protein has an important physiological role, which, however, has remained to be sufficiently elucidated. Previous studies by our group have demonstrated that TNFAIP1 interacts with proliferating cell nuclear antigen and the small p50 sub-unit of DNA polymerase δ, implying that it may be involved in DNA synthesis and DNA repair (2, 3) . Another group reported that Ras homolog gene family, member B (RhoB) induces apoptosis by interacting with TNFAIP1 via a c-Jun N-terminal kinase-mediated signaling mechanism, suggesting that TNFAIP1 is involved in apoptosis (4) . Furthermore, TNFAIP1 is an adaptor for cullin 3 to control RhoA degradation and regulate the structure of the RhoA-associated actin cytoskeleton (5) . In addition, the transcription levels of TNFAIP1 were robustly induced in the brain of a transgenic Caenorhabditis elegans model of Alzheimer's disease (AD), indicating that TNFAIP1 may also be involved in AD development (6) . Therefore, inhibition of TNFAIP1 expression may be beneficial for neuronal cells under pathological conditions, for which the elucidation of the transcriptional regulation mechanisms of TNFAIP1 expression is required. Previous studies have shown that transcription factor Sp1 is capable of controlling basal TNFAIP1 expression by directly binding to the proximal promoter region of human TNFAIP1 (7) . However, the transcriptional regulation mechanisms have largely remained elusive. The present study aimed to determine the effects of neuroprotective agents with activity against AD on the expression of TNFAIP1 in SKNSH human neuroblastoma cells using reverse-transcription polymerase chain reaction (RT-qPCR) analysis and a luciferase reporter assay. As forskolin (8) and genistein (9) have been demonstrated to potently stimulate cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB)-mediated transcription (8) , the present study investigated the role of transcription factor CREB in the regulation of TNFAIP1. Further mechanistic studies were performed by examining the effects of KG-501, a specific CREB inhibitor (10) , and overexpression of wild-type (WT) CREB or CREB mutated at ser133a (CREBs133a) or at its DNA-binding site (KCREB) on the expression of TNFAIP1 expression as well as on TNFAIP1 promoter activity in SKNSH cells. Furthermore, the present study aimed to identify the corresponding CREB binding sites in the promoter region of TNFAIP1, which were verified using luciferase reporter and chromatin immunoprecipitation (ChIP) assays. The present study elucidated the regulatory mechanisms of TNFAIP1 by CREB, which will be useful for future studies regarding the regulation of TNFAIP1 and the development of TNFAIP1-targeted therapeutics of neuronal disease.
Materials and methods

Materials. Lipofectamine
TM 2000, Dulbecco's modified Eagle's medium (DMEM), glutamine, penicillin and streptomycin were purchased from Invitrogen Life Technologies, Inc., Carlsbad, CA, USA). Fetal bovine serum (FBS) and 0.25% trypsin-EDTA were purchased from Gibco-BRL (Invitrogen Life Technologies, Inc.). Chemical compounds including dimethyl sulfoxide (DMSO), forskolin, valproic acid, polydatin, genistein, KG-501 and mouse monoclonal anti-β-actin antibody, were purchased from Sigma-Aldrich (St. Louis, MO, USA). Rabbit polyclonal anti-TNFAIP1 antibody, was custom-made by Nanjing Chuanbo Bioch Co. Ltd (Nanjing, China) according to the protocol of a previous study (3) . Rabbit polyclonal anti-CREB antibody was purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). Cytomegalovirus plasmid (pCMV)-Myc and the CREB dominant-negative vector set, including pCMV-CREB, pCMV-CREBs133a, containing a mutation of the phosphorylatable serine 133, and pCMV-KCREB, containing a mutation of the DNA binding domain, were purchased from Clontech Inc. (Mountainview, CA, USA). pGEM ® -T Easy Vector System II, pGL3-Basic vector and the Dual-Luciferase ® Reporter Assay System were purchased from Promega (Madison, WI, USA). LA Taq™ DNA Polymerase with GC buffers was purchased from Takara (Otsu, Japan). The real-time PCR primers for human TNFAIP1 and β-actin were purchased from Qiagen GmbH (Hilden, Germany).
Reporter plasmid construction. The TNFAIP1 promoter region was previously characterized by Liu et al (7) . The proximal 5' region of human TNFAIP1 promoter region spanning from nucleotide -1087 to nucleotide -139 (GenBank accession number, NM_021137) was amplified by PCR using the forward primer P-948F (5'-GGGGTACCCCACA CATAACTGGCACTCA-3') and the reverse primer P-948R (5'-AAGCTTTCTCAGCAGCTGGGTGGCCA-3') using the genomic DNA of SKNSH cells as a template, and ligated into the pGL3-basic vector in the KpnI/HindIII sites, denoted as P-948 (-1087/-139). PCR was performed using a thermocycler (Eppendorf Mastercycler ® Nexus; Eppendorf, Hamburg, Germany) with the following conditions: Initial denaturation of DNA, 94˚C for 10 min; denaturation, 32 cycles of 95˚C for 45 sec; annealing, 58˚C for 30 sec; extension, 72˚C for 40 sec; and final extension, 72˚C for 5 min. The sequence of the promoter region of CRE from -1087 to -139 bp was predicted by Jaspar (http://jaspar.genereg.net/). Deletion of the CRE1 and CRE2 sites located at -285 and -425 bp was performed using overlapping extension PCR, as described previously (11) . In brief, in the first round, two PCRs were performed in parallel using P-948 (-1087/-139) as a template: One PCR was performed with the forward primer P-948F and a reverse primer containing a CRE1-site deletion [Pr(p)CRE1mR (5'-GAA GGT AGT GTA GGT AAA CAG GCT-3')] or a primer containing a CRE2-site deletion [Pr(p)CRE2mR (5'-AGG TAG GCG GTC GGG GGA CGC GGG-3')]; the other PCR was performed with a forward primer containing a CRE1-site mutation [Pr(p)CRE1mF (5'-TTT ACC TAC ACT ACC TTC CTG ACTC-3')] or a forward primer containing a CRE2-site mutation [Pr(p) CRE2mF (5'-CCC CCG ACC GCC TAC CTG CCG GCCC-3')] and the reverse primer P-1152R. In the second round, an equimolar mixture of the two PCR products was used as template with P-1152F and P-1152R primers. The final PCR products were then cloned into pGL3-Basic vector in the KpnI/HindIII sites, denoted as P-948 (CRE1del) or P-948 (CRE2del). The above-mentioned PCR amplifications were performed using the Advantage 2 PCR kit (cat no. 639207; Clontech Laboratories, Inc., Mountainview, CA, USA). All primers were purchased from Sheng-Gong Technologies (Shanghai, China), and the construct sequences were confirmed by sequencing performed by Sheng-Gong Technologies.
Cell culture and transfection. SKNSH cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and routinely cultured in a humidified atmosphere of 5% CO 2 at 37˚C in DMEM supplemented with 10% fetal bovine serum, 0.3 mM glutamine and 50 U/ml penicillin/streptomycin. Transient transfections were performed in cells at 70% confluence using Lipofectamine™ 2000 reagent according to the manufacturer's instructions. After transfection for 4 h, the transfection medium was replaced with DMEM.
Luciferase reporter assay. The luciferase assay was performed as previously described (12) . In brief, SKNSH cells were transiently transfected with DNA constructs as well as pRL-TK, which was used as control for transfection efficiency. Cells were incubated for 24 h after transfection and were treated with reagents, including DMSO, polydatin (10 µM), valproic acid (10 µM), forskolin (10 µM) and genistein (10 µM) for another 24 h. The cells were finally harvested and lysed using 1X passive lysis buffer, and luciferase activity was assessed utilizing the Dual-Luciferase RT-PCR analysis. After treatment with drugs including DMSO (10 µM), forskolin (10 µM), valproic acid (10 µM), polydatin (10 µM) or genistein (10 µM) for 24 h, the SKNSH cells were harvested for extraction of total RNA using TRIzol (Invitrogen Life Technologies, Inc.). Total mRNA was reversely transcribed into cDNA using the Superscript system (Invitrogen Life Technologies, Inc.). TNFAIP1 expression was analyzed by RT-PCR using a SYBR green kit (cat no. 4367659; Applied Biosystems Life Technologies, Foster City, CA, USA) according to the manufacturer's instructions on an ABI 7500 detection system (Applied Biosystems Life Technologies). The thermocycling conditions were as follows: Initial denaturation of DNA, 94˚C for 5 min; denaturation, 32 cycles of 95˚C for 30 sec; annealing, 60˚C for 30 sec; extension, 72˚C for 30 sec; and final extension, 72˚C for 5 min. The RNA levels were determined using the 2 -ΔΔCt method and expressed as the fold-change of TNFAIP1 expression in forskolin, valproic acid, polydatin or genistein-treated cells relative to DMSO-treated cells after normalization to the housekeeping gene β-actin.
Western blot analysis. Cell lysates were extracted from the SKNSH cells using M-PER Mammalian Protein Extraction Reagent (Cell Signaling Technology, Inc.) containing protease inhibitor (100X; Sigma-Aldrich, St. Louis, MO, USA), and the concentration of total proteins was determined by a Bicinchoninic Acid Protein assay kit (Pierce Biotechnology, Inc., Rockford, IL, USA). Protein (20 µg) extracted from SKNSH cells was separated by 4-12% SDS-PAGE (Invitrogen Life Technologies, Inc.) and transferred onto a nitrocellulose membrane (EMD Millipore, Billerica, MA, USA) using the iBlot ® dry blotting system (Invitrogen Life Technologies, Inc.). The membranes were blocked for 1 h at room temperature in 5% non-fat dried milk in 10 mM phosphate-buffered saline (PBS; pH 7.2). Immunoblotting was then performed at 4˚C overnight by incubation with the following primary antibodies: Rabbit polyclonal TNFAIP1 antibody (1:1,000; custom-made; Nanjing Chuanbo Biotech Co., Ltd., Nanjing, China), rabbit polyclonal CREB antibody (1:1,000; cat no. 4820; Cell Signaling Technology, Inc.) or mouse monoclonal β-actin antibody (1:5,000; cat no. A3854; Sigma-Aldrich). Following incubation with species-appropriate, horseradish peroxidase-conjugated secondary antibodies (1:5,000; cat no. M21001 for goat anti-mouse IgG-HRP; cat no. M21002 for goat anti-rabbit IgG-HRP; Abmart, Shanghai, China) for 1 h at room temperature, immunoreactive proteins were detected using enhanced chemiluminescence (ECL detection system; Amersham Pharmacia Biotech; GE Healthcare, Little Chalfont, UK) according to the manufacturer's instructions and then exposed to film (X-Omat; Eastman Kodak Co., Rochester, NY, USA). The intensity of the chemiluminescence signal was quantified by densitometry using ImageJ software version 1.49 (National Institutes of Health, Bethesda, MD, USA).
ChIP assay. ChIP assays were performed using the EZChIP™ kit (Upstate Biotechnology, EMD Millipore, Billerica, MA, USA) according to the manufacturer's instructions as previously described (12) . In brief, ~1x10
6 SKNSH cells were cross-linked with 1% formaldehyde and collected for sonication to shear the chromatin with an average size of ~300 bp. Immunoprecipitation was then performed with anti-CREB antibody or control rabbit polyclonal immunoglobulin (Ig)G antibody. The DNA-protein complexes were then reverse cross-linked at 65˚C for 3 h. DNA from these samples was subjected to PCR with the following conditions: DNA initial denaturation, 94˚C for 10 min; denaturation, 32 cycles of 95˚C for 50 sec; annealing, 58˚C for 30 sec; extension, 72˚C for 50 sec; and final extension, 72˚C for 5 min. Primer sets used for amplifying a 285-bp fragment spanning the 519-234 bp region of the TNFAIP1 promoter were Ch-F (5'-GAA TTC CCA CGT CTC TCC CC-3') and Ch-R (5'-ATG GGG GCT GTA AGT GCT TC-3'). 18s ribosomal (r)RNA PCR was performed as a negative control. Primer sets used for amplifying a 233-bp DNA fragment corresponding to a region lacking CRE on the human 18s rRNA gene promoter were h18sF (5'-GTA ACC CGT TGA ACC CCA TT-3') and h18sR (5'-CCA TCC AAT CGG TAG TAG CG-3'). The Agarose gel was prepared with 1.5% gel strength containing 1.0 µg/ml ethidium bromide (Sheng-Gong Technologies). PCR products were subjected to agarose gel electrophoresis (30 V for 1 h) using the gel electrophoresis module (Beijing Liuyi Instrument Factory, Beijing, China).
Statistical analysis.
Values are expressed as the mean ± standard deviation of at least three independent experiments. Statistical analysis was performed using SPSS 18.0 software 
Results
Forskolin inhibits mRNA expression of TNFAIP1 and TNFAIP1
promoter activity in SKNSH cells. As TNFAIP1 was indicated to be involved in neuronal damage associated with AD, the present study hypothesized that neuroprotective agents with activity against AD may target TNFAIP1. A group of chemical compounds, including valproic acid (13), polydatin (14) , forskolin (15) and genistein (16) have been reported to exhibit therapeutic potential in AD. The effects of these chemical compounds on human TNFAIP1 transcription and promoter activity in SKNSH cells were thus determined by RT-PCR and luciferase assay, respectively. The results showed that forskolin significantly inhibited human TNFAIP1 mRNA levels in SKNSH cells (Fig. 1A) . Similarly, forskolin and genistein significantly attenuated the activity of the P-948 (-1087/-139) TNFAIP1 promoter (Fig. 1B) . Forskolin is a selective activator of adenylate cyclase that potently increases phosphorylation of CREB on its ser-133 site to stimulate CREB-mediated transcription (17); thus, CREB may be involved in the regulation of TNFAIP1 expression by forskolin.
CREB acts as a negative transcriptional regulator of TNFAIP1 expression.
To examine the roles of CREB in TNFAIP1 regulation, the present study used CREB inhibitor KG-501. The results showed that KG-501 significantly increased the protein expression of TNFAIP1 in SKNSH cells ( Fig. 2A) . Next, the present study examined the effects of CREB and dominant-mutant CREB vectors (KCREB and CREBs133a) on the protein expression of TNFAIP1. As expected, overexpression of CREB resulted in a decrease in TNFAIP1 protein expression, while KCREB or CREBs133a had no significant effect (Fig. 2B) . Furthermore, the present study evaluated the effects of CREB on TNFAIP1 promoter activity. SKNSH cells were transiently transfected with P-948 (-1087/-139) and WT CREB expression vector or dominant-mutant CREB vectors (KCREB and CREBs133a). WT CREB, but not the dominant-mutant CREB vectors significantly reduced TNFAIP1 promoter activity (Fig. 2C ). In conclusion, these results suggested that CREB negatively regulates TNFAIP1 expression.
CREB suppresses TNFAIP1 promoter activity through CREs.
As CREB repressed TNFAIP1 promoter activity, the present study further analyzed the potential CREs that are able to bind to CREB at sites located in the region of -1087 to -139 by using the bioinformatics transcription factor binding site prediction tool Jaspar (http://jaspar.genereg.net/). Two putative cAMP response elements, designated CRE1 and CRE2, were discovered at -285 and -425 bp, respectively (Fig. 3A) . To investigate whether these CRE sites mediate CREB-decreased TNFAIP1 promoter activity, deleting mutations of these two CRE sites were generated (Fig. 3B) . SKNSH cells were co-transfected with CREB expression vector or empty vector as well as P-948 (-1087/-139), P-984 (CRE1del) or P-984 (CRE2del). A luciferase assay showed that CREB overexpression significantly 
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decreased the promoter activity of P-948 (-1087/-139), while CREB overexpression did not cause inhibition of the promoter activity of P-948 (CRE1del) and P-948 (CRE2del; Fig. 3C ). These results indicate that CRE1 and CRE2 are involved in the suppression of TNFAIP1 expression by CREB.
CREB is capable of binding to the TNFAIP1 promoter.
The present study further investigated whether CREB suppresses TNFAIP1 gene expression through directly binding to the TNFAIP1 promoter. To test this, ChIP assays were performed with CREB antibody or IgG controls in SKNSH cells. DNA precipitated by ChIP was amplified by PCR using TNFAIP1
promoter-specific primers covering the two CRE sites from -519 bp to -234 bp or 18s rRNA promoter primers lacking CRE sites. Analysis of the PCR products by gel electrophoresis showed that CREB was able to bind to the promoter region of TNFAIP1 covering two CREs, but not to the 18s rRNA lacking CRE sites (Fig. 4) . ChIP PCR therefore confirmed that CREB binds to the TNFAIP1 promoter region in SKNSH cells.
Forskolin decreases TNFAIP1 expression mediated by CREB phosphorylation on ser133.
The results of the present study suggested that CREB is a negative regulator for TNFAIP1 expression. Therefore, it was further investigated whether CREB is involved in forskolin-induced inhibition of TNFAIP1 expression. In accordance with the results shown in Figs. 1B and 2C, treatment with forskolin or CREB overexpression significantly decreased TNFAIP1 promoter activity, and forskolin combined with CREB overexpression further reduced TNFAIP1 promoter activity (Fig. 5) . However, although an Figure 5 . Phosphorylation of CREB on ser133 is necessary for forskolin-induced inhibition of human TNFAIP1 promoter activity. Relative luciferase activity was determined after co-transfection of P-948 luciferase reporter plasmid containing the (-1087/-139 bp) promoter region of TNFAIP1 with CREB or its dominant-negative mutant for 24 h, followed by treatment with DMSO or forskolin for another 24 h. Values are expressed as the mean ± standard deviation (n=3). identical dose of forskolin was used, TNFAIP1 promoter activity was partially restored in CREBs133a-transfected cells (Fig. 5) . These results indicated that CREB phosphorylation on ser133 is responsible for forskolin-induced inhibition of TNFAIP1 expression.
Discussion
TNFAIP1 has been suggested to be an apoptosis-associated protein (4) and involved in the development of AD (6) . Therefore, TNFAIP1 is likely to be implicated in neuronal damage associated with neurodegenerative disease. Indeed, this notion was confirmed by experiments performed in our group, which demonstrated that inhibition of TNFAIP1 expression decreased Aβ-induced neuronal toxicity (unpublished data). Therefore, inhibition of TNFAIP1 expression under neuropathological conditions may have neuroprotective effects. Elucidation of the transcriptional regulation mechanisms of TNFAIP1 may aid in the development of therapeutics for neuronal disease targeting TNFAIP1. The present study was the first, to the best of our knowledge, to demonstrate that CREB is a critical transcription factor for the negative regulation of TNFAIP1 transcription in SKNSH cells.
Given that TNFAIP1 is implicated in the development of AD and is induced in the generation of animal models of AD, therapeutic drugs with activity against AD have been hypothesized to inhibit TNFAIP1 expression. In the present study, a number of well-known natural products, including polydatin, valproic acid, forskolin and genistein, were selected for the evaluation of their inhibitory effects on TNFAIP1 expression, as they have been demonstrated to be potentially protective against AD (13) (14) (15) (16) . The results showed that polydatin and valproic acid slightly inhibited TNFAIP1 promoter activity. Of note, forskolin and genistein significantly suppressed TNFAIP1 promoter activity. To date, no study has indicated that polydatin is able to activate CREB, whereas valproic acid (18), forskolin (8) and genistein (9) are known to potently stimulate the phosphorylation of CREB at ser133 and consequently activate CREB-mediated transcription (8) . These findings indicated that transcription factor CREB may be a potential inhibitor of TNFAIP1 expression in neuronal cells. Genistein is a known phytoestrogen with marked structural and functional similarity with 17β-estradiol (19) . A recent study suggested that 17β-estradiol is a negative regulator of TNFAIP1 in mouse hippocampi (20) . These findings were consistent with the results of the present study, demonstrating that TNFAIP1 expression was negatively regulated by genistein.
CREB is a key transcription factor that is tightly linked with neuronal cell survival and apoptosis (21, 22) . Upon stimulation, CREB is phosphorylated at ser133 and subsequent recruited to CRE (23, 24) . As expected, the present study revealed that overexpression of WT CREB, but not mutated CREB (CREBs133a and KCREB) significantly inhibited TNFAIP1 promoter activity as well as protein expression. In addition, the present study demonstrated that WT CREB promoted forskolin-induced inhibition of TNFAIP1 promoter activity, which was, however, partially rescued by overexpression of CREBs133a. It has been suggested that dominant-negative CREB interfered with the function of the phosphorylated CREB, possibly via the formation of inactive heterodimers (25) . Thus, based on the results of the present study, phosphorylation of CREB at ser133 is necessary for CREB-induced downregulation of TNFAIP1 and activation of upstream signaling pathways leading to CREB phosphorylation may thus intervene with TNFAIP1 expression.
As it was demonstrated that TNFAIP1 promoter activity was inhibited by transcription factor CREB, the present study further analyzed the CRE sites in the TNFAIP1 promoter spanning from -1087 to -139 bp. Two CRE sites, CRE1 and CRE2, were identified using bioinformatics analysis. In fact, a previous study indicated that site-directed mutagenesis of the CRE1 site had no effect on the basal TNFAIP1 promoter activity (7) . However, the results of the present study showed that a deleting mutation of CRE1 and CRE2 inhibited the CREB-induced reduction of TNFAIP1 promoter activity. It is possible that CREB binds to the CRE1 site upon stimulation, but not under basal conditions. Although the ChIP assay of the present study showed that CREB was able to bind to the TNFAIP1 promoter region from -519 to -234 bp covering the two CRE sites, is not possible to conclude that CREB specifically binds to CRE1 or CRE2 sites. Further study is required to determine whether CREB specifically interacts with the CRE1 or the CRE2 site under basal and pathological conditions.
In conclusion, the present study suggested that forskolin suppressed the expression of pro-apoptotic protein TNFAIP1 through activating neuronal survival mediator CREB. Recent experiments performed in our group have shown that overexpression of TNFAIP1 in neuronal cells induces significant neuronal apoptosis (unpublished data). Therefore, the present study links neuronal survival mediator CREB and apoptosis-associated protein TNFAIP1, which is likely to be involved in the development of AD. The present study thus provided a molecular basis for the intervention of neuronal disorders by targeting TNFAIP1. Whether the expression of TNFAIP1 is associated with neuropathological conditions will be investigated in future studies.
